MSD, Samsung's Glargine Biosimilar Hits Phase III Endpoints
This article was originally published in PharmAsia News
Executive Summary
MSD has unveiled positive new results from two Phase III clinical trials with its investigational insulin glargine biosimilar, and the progress is set to further accelerate the commercialization of the diverse biosimilar pipeline at partner Samsung Bioepis, which is partially funding development of the product.